Angela Poerio

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Clinical Cancer Research · 2006 · 512 citations · Full text

Medicine, Hematology, Oncology +15

ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Giovanni Martinelli, Gianantonio Rosti et al. · Journal of Clinical Oncology · 2005 · 372 citations · Full text

Medicine, Hematology, Pharmacology +14

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

Gianantonio Rosti, Francesca Palandri, Fausto Castagnetti et al. · Blood · 2009 · 211 citations · Full text

Medicine, Oncology, Pharmacology +7

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

Simona Soverini, Alessandra Gnani, Sabrina Colarossi et al. · Blood · 2009 · 174 citations · Full text

Medicine, Genetics, Oncology +16

Denaturing-HPLC-Based Assay for Detection of ABL Mutations in Chronic Myeloid Leukemia Patients Resistant to Imatinib

Simona Soverini, Giovanni Martinelli, Marilina Amabile et al. · Clinical Chemistry · 2004 · 121 citations

Medicine, Hematology, Pharmacology +13